Study of ALN's OATF Vena Cava Filter

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

Migration of a thrombus in the pulmonary circulation is the leading cause of pulmonary embolism (PE). It can be prevented mechanically by implanting a vena cava filter (VCF) in the inferior vena cava. The implation of a VCF is indicated for patients with acute PE and a contraindication to anticoagulation, with an acute deep vein thrombosis (DVT) without PE and a contraindication to anticoagulation or with acute venous thromboembolism (less than 3 months) in whom an interventional gesture at hemorrhagic and thromboembolic risk contraindicates anticoagulation. The purpose of this study is to describe the rates of implantation, removal and complications associated with the use of the optional ALN OATF VCF in current practice.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient implanted with an ALN OATF VCF

• Patient informed

Locations
Other Locations
France
AP-HP - Hôpital Européen Georges-Pompidou Paris, France
RECRUITING
Paris
Contact Information
Primary
Breno MELO, PhD
gestion-locale.drc@aphp.fr
+33140271840
Backup
Carole Déan, PhD
carole.dean@aphp.fr
+33156093719
Time Frame
Start Date: 2023-02-14
Estimated Completion Date: 2026-02
Participants
Target number of participants: 50
Treatments
Vena Cava Filter
Participants implanted with the vena cava filter OATF (ALN)
Sponsors
Collaborators: Aln2b SARL
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov